Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.40 |
| ▸ | RXRA | P19793 | 9/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827558 | 0.84 | GRIN2B (0.45) | GRIN2BRXRAGRIN1KCNH2PDE4A | |
| SCHEMBL27021902 | 0.81 | ALDH1A1 (0.51) | USP2ALDH1A1GAAPKMHPGD | |
| SCHEMBL19965694 | 0.79 | LMNA (0.47) | USP2ALDH1A1GAAPKMHPGD | |
| SCHEMBL6024128 | 0.77 | AKR1C3 (0.52) | ALDH1A1GAA | |
| SCHEMBL19232060 | 0.76 | CYP2C19 (0.40) | USP2ALDH1A1GAAPKMHPGD | |
| SCHEMBL27363114 | 0.76 | ALDH1A1 (0.48) | USP2ALDH1A1GAAPKMHPGD | |
| SCHEMBL18848621 | 0.76 | ALDH1A1 (0.48) | USP2ALDH1A1GAAPKMHPGD | |
| SCHEMBL9963710 | 0.76 | ALDH1A1 (0.48) | USP2ALDH1A1GAAPKMHPGD | |
| SCHEMBL16770733 | 0.76 | ALDH1A1 (0.48) | USP2ALDH1A1GAAPKMHPGD | |
| SCHEMBL25027442 | 0.76 | GRIN2B (0.47) | GRIN2BRXRAGRIN1ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020249796-A1 | PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | GRIN2B 2098/4885RXRA 3423/4885GRIN1 1613/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | GRIN2B 2098/4885RXRA 3423/4885GRIN1 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.